{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T18:01:38Z","timestamp":1793296898883,"version":"4.5.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,1,10]],"date-time":"2022-01-10T00:00:00Z","timestamp":1641772800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,1,10]],"date-time":"2022-01-10T00:00:00Z","timestamp":1641772800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81401117"],"award-info":[{"award-number":["81401117"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Transl Psychiatry"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Mitochondrial dysfunction has been implicated in the risk, pathophysiology, and progression of mood disorders, especially bipolar disorder (BD). Thus, the objective of this meta-analysis was to determine the overall antidepressant effect of mitochondrial modulators in the treatment of bipolar depression. Outcomes included improvement in depression scale scores, Young Mania Rating Scale (YMRS) and Clinical Global Impression-Severity Scale (CGI-S) score. Data from randomized controlled trials (RCTs) assessing the antidepressant effect of diverse mitochondrial modulators were pooled to determine standard mean differences (SMDs) compared with placebo.13 RCTs were identified for qualitative review. The overall effect size of mitochondrial modulators on depressive symptoms was \u22120.48 (95% CI: \u22120.83 to \u22120.14, <jats:italic>p<\/jats:italic>\u2009=\u20090.007, <jats:italic>I<\/jats:italic><jats:sup>2<\/jats:sup>\u2009=\u200975%), indicative of a statistically significant moderate antidepressant effect. In the subgroup analysis, NAC improved depressive symptoms compared with placebo (\u22120.88, 95% CI: \u22121.48 to \u22120.27, <jats:italic>I<\/jats:italic><jats:sup>2<\/jats:sup>\u2009=\u200981%). In addition, there was no statistical difference between mitochondrial modulators and placebo in YMRS. Although mitochondrial modulators were superior to placebo in CGI-S score (\u22120.44, 95% CI: \u22120.83 to \u22120.06, <jats:italic>I<\/jats:italic><jats:sup>2<\/jats:sup>\u2009=\u200971%), only EPA was superior to placebo in subgroup analysis. Overall, a moderate antidepressant effect was observed for mitochondrial modulators compared with placebo in the treatment of bipolar depression. The small number of studies, diversity of agents, and small sample sizes limited interpretation of the current analysis.<\/jats:p>","DOI":"10.1038\/s41398-021-01727-7","type":"journal-article","created":{"date-parts":[[2022,1,10]],"date-time":"2022-01-10T12:04:21Z","timestamp":1641816261000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Mitochondrial modulators in the treatment of bipolar depression: a systematic review and meta-analysis"],"prefix":"10.1038","volume":"12","author":[{"given":"Liang","family":"Liang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junyu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8947-9921","authenticated-orcid":false,"given":"Gaohua","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,1,10]]},"reference":[{"key":"1727_CR1","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1016\/S0140-6736(15)00241-X","volume":"387","author":"I Grande","year":"2016","unstructured":"Grande I, Berk M, Birmaher B, Vieta E. Bipolar disorder. Lancet. 2016;387:1561\u201372.","journal-title":"Lancet"},{"key":"1727_CR2","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1111\/bdi.12087","volume":"15","author":"M Pompili","year":"2013","unstructured":"Pompili M, Gonda X, Serafini G, Innamorati M, Sher L, Amore M, et al. Epidemiology of suicide in bipolar disorders: a systematic review of the literature. Bipolar Disord. 2013;15:457\u201390.","journal-title":"Bipolar Disord"},{"key":"1727_CR3","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1177\/0269881116636545","volume":"30","author":"GM Goodwin","year":"2016","unstructured":"Goodwin GM, Haddad PM, Ferrier IN, Aronson JK, Barnes T, Cipriani A, et al. Evidence-based guidelines for treating bipolar disorder: revised third edition recommendations from the British Association for Psychopharmacology. J Psychopharmacol. 2016;30:495\u2013553.","journal-title":"J Psychopharmacol"},{"key":"1727_CR4","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1177\/0004867412449303","volume":"47","author":"AA Nierenberg","year":"2013","unstructured":"Nierenberg AA, Kansky C, Brennan BP, Shelton RC, Perlis R, Iosifescu DV. Mitochondrial modulators for bipolar disorder: a pathophysiologically informed paradigm for new drug development. Aust N Z J Psychiatry. 2013;47:26\u201342.","journal-title":"Aust N Z J Psychiatry"},{"key":"1727_CR5","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.1016\/S0140-6736(18)32548-0","volume":"392","author":"R Barnett","year":"2018","unstructured":"Barnett R. Bipolar disorder. Lancet. 2018;392:1510.","journal-title":"Lancet"},{"key":"1727_CR6","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1111\/pcn.12852","volume":"73","author":"T Kato","year":"2019","unstructured":"Kato T. Current understanding of bipolar disorder: Toward integration of biological basis and treatment strategies. Psychiatry Clin Neurosci. 2019;73:526\u201340.","journal-title":"Psychiatry Clin Neurosci"},{"key":"1727_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.neubiorev.2017.01.014","volume":"74","author":"G Morris","year":"2017","unstructured":"Morris G, Walder K, McGee SL, Dean OM, Tye SJ, Maes M, et al. A model of the mitochondrial basis of bipolar disorder. Neurosci Biobehav Rev. 2017;74:1\u201320.","journal-title":"Neurosci Biobehav Rev"},{"key":"1727_CR8","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1590\/1516-4446-2013-1341","volume":"37","author":"OM Dean","year":"2015","unstructured":"Dean OM, Turner A, Malhi GS, Ng C, Cotton SM, Dodd S, et al. Design and rationale of a 16-week adjunctive randomized placebo-controlled trial of mitochondrial agents for the treatment of bipolar depression. Braz J Psychiatry. 2015;37:3\u201312.","journal-title":"Braz J Psychiatry"},{"key":"1727_CR9","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1016\/j.biopsych.2008.04.022","volume":"64","author":"M Berk","year":"2008","unstructured":"Berk M, Copolov DL, Dean O, Lu K, Jeavons S, Schapkaitz I, et al. N-acetyl cysteine for depressive symptoms in bipolar disorder\u2014a double-blind randomized placebo-controlled trial. Biol Psychiatry. 2008;64:468\u201375.","journal-title":"Biol Psychiatry"},{"key":"1727_CR10","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1590\/S1516-44462011000400011","volume":"33","author":"PV Magalh\u00e3es","year":"2011","unstructured":"Magalh\u00e3es PV, Dean OM, Bush AI, Copolov DL, Malhi GS, Kohlmann K, et al. N-acetylcysteine for major depressive episodes in bipolar disorder. Braz J Psychiatry. 2011;33:374\u20138.","journal-title":"Braz J Psychiatry"},{"key":"1727_CR11","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-019-1257-1","volume":"17","author":"M Berk","year":"2019","unstructured":"Berk M, Turner A, Malhi GS, Ng CH, Cotton SM, Dodd S, et al. A randomised controlled trial of a mitochondrial therapeutic target for bipolar depression: mitochondrial agents, N-acetylcysteine, and placebo. BMC Med. 2019;17:18.","journal-title":"BMC Med"},{"key":"1727_CR12","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1016\/j.jad.2018.10.083","volume":"245","author":"PK Ellegaard","year":"2019","unstructured":"Ellegaard PK, Licht RW, Nielsen RE, Dean OM, Berk M, Poulsen HE, et al. The efficacy of adjunctive N-acetylcysteine in acute bipolar depression: a randomized placebo-controlled study. J Affect Disord. 2019;245:1043\u201351.","journal-title":"J Affect Disord"},{"key":"1727_CR13","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1001\/archpsyc.56.5.407","volume":"56","author":"AL Stoll","year":"1999","unstructured":"Stoll AL, Severus WE, Freeman MP, Rueter S, Zboyan HA, Diamond E, et al. Omega 3 fatty acids in bipolar disorder: a preliminary double-blind, placebo-controlled trial. Arch Gen Psychiatry. 1999;56:407\u201312.","journal-title":"Arch Gen Psychiatry"},{"key":"1727_CR14","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1192\/bjp.188.1.46","volume":"188","author":"S Frangou","year":"2006","unstructured":"Frangou S, Lewis M, McCrone P. Efficacy of ethyl-eicosapentaenoic acid in bipolar depression: randomised double-blind placebo-controlled study. Br J Psychiatry. 2006;188:46\u201350.","journal-title":"Br J Psychiatry"},{"key":"1727_CR15","doi-asserted-by":"publisher","first-page":"1922","DOI":"10.1176\/ajp.161.10.1922","volume":"161","author":"F Hirashima","year":"2004","unstructured":"Hirashima F, Parow AM, Stoll AL, Demopulos CM, Damico KE, Rohan ML, et al. Omega-3 fatty acid treatment and T(2) whole brain relaxation times in bipolar disorder. Am J Psychiatry. 2004;161:1922\u20134.","journal-title":"Am J Psychiatry"},{"key":"1727_CR16","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1097\/JCP.0000000000000938","volume":"38","author":"M Mehrpooya","year":"2018","unstructured":"Mehrpooya M, Yasrebifar F, Haghighi M, Mohammadi Y, Jahangard L. Evaluating the effect of coenzyme Q10 augmentation on treatment of bipolar depression: a Double-Blind Controlled Clinical Trial. J Clin Psychopharmacol. 2018;38:460\u20136.","journal-title":"J Clin Psychopharmacol"},{"key":"1727_CR17","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1007\/s00702-017-1817-5","volume":"125","author":"RA Toniolo","year":"2018","unstructured":"Toniolo RA, Silva M, Fernandes F, Amaral J, Dias R, Lafer B. A randomized, double-blind, placebo-controlled, proof-of-concept trial of creatine monohydrate as adjunctive treatment for bipolar depression. J Neural Transm. 2018;125:247\u201357.","journal-title":"J Neural Transm"},{"key":"1727_CR18","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1034\/j.1399-5618.2000.020107.x","volume":"2","author":"KN Chengappa","year":"2000","unstructured":"Chengappa KN, Levine J, Gershon S, Mallinger AG, Hardan A, Vagnucci A, et al. Inositol as an add-on treatment for bipolar depression. Bipolar Disord. 2000;2:47\u201355.","journal-title":"Bipolar Disord"},{"key":"1727_CR19","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1111\/j.1399-5618.2006.00303.x","volume":"8","author":"A Eden Evins","year":"2006","unstructured":"Eden Evins A, Demopulos C, Yovel I, Culhane M, Ogutha J, Grandin LD, et al. Inositol augmentation of lithium or valproate for bipolar depression. Bipolar Disord. 2006;8:168\u201374.","journal-title":"Bipolar Disord"},{"key":"1727_CR20","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.jpsychires.2017.07.021","volume":"95","author":"WK Marsh","year":"2017","unstructured":"Marsh WK, Penny JL, Rothschild AJ. Vitamin D supplementation in bipolar depression: a double blind placebo controlled trial. J Psychiatr Res. 2017;95:48\u201353.","journal-title":"J Psychiatr Res"},{"key":"1727_CR21","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1097\/JCP.0b013e31829a83f5","volume":"33","author":"BP Brennan","year":"2013","unstructured":"Brennan BP, Jensen JE, Hudson JI, Coit CE, Beaulieu A, Pope HG, et al. A placebo-controlled trial of acetyl-l-carnitine and alpha-lipoic acid in the treatment of bipolar depression. J Clin Psychopharmacol. 2013;33:627\u201335.","journal-title":"J Clin Psychopharmacol"},{"key":"1727_CR22","doi-asserted-by":"publisher","first-page":"3481","DOI":"10.1007\/s00213-020-05629-2","volume":"237","author":"T Kishi","year":"2020","unstructured":"Kishi T, Miyake N, Okuya M, Sakuma K, Iwata N. N-acetylcysteine as an adjunctive treatment for bipolar depression and major depressive disorder: a systematic review and meta-analysis of double-blind, randomized placebo-controlled trials. Psychopharmacology. 2020;237:3481\u20137.","journal-title":"Psychopharmacology"},{"key":"1727_CR23","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1111\/bdi.12373","volume":"18","author":"JD Rosenblat","year":"2016","unstructured":"Rosenblat JD, Kakar R, Berk M, Kessing LV, Vinberg M, Baune BT, et al. Anti-inflammatory agents in the treatment of bipolar depression: a systematic review and meta-analysis. Bipolar Disord. 2016;18:89\u2013101.","journal-title":"Bipolar Disord"},{"key":"1727_CR24","doi-asserted-by":"publisher","first-page":"b2535","DOI":"10.1136\/bmj.b2535","volume":"339","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG, Prisma G. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009;339:b2535.","journal-title":"BMJ"},{"key":"1727_CR25","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"JP Higgins","year":"2003","unstructured":"Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557\u201360.","journal-title":"BMJ"},{"key":"1727_CR26","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1111\/acps.12343","volume":"130","author":"DM Taylor","year":"2014","unstructured":"Taylor DM, Cornelius V, Smith L, Young AH. Comparative efficacy and acceptability of drug treatments for bipolar depression: a multiple-treatments meta-analysis. Acta Psychiatr Scand. 2014;130:452\u201369.","journal-title":"Acta Psychiatr Scand"},{"key":"1727_CR27","doi-asserted-by":"publisher","first-page":"e457","DOI":"10.4088\/JCP.15r09984","volume":"77","author":"BS Fernandes","year":"2016","unstructured":"Fernandes BS, Dean OM, Dodd S, Malhi GS, Berk M. N-Acetylcysteine in depressive symptoms and functionality: a systematic review and meta-analysis. J Clin Psychiatry. 2016;77:e457\u201366.","journal-title":"J Clin Psychiatry"}],"container-title":["Translational Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41398-021-01727-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41398-021-01727-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41398-021-01727-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T15:19:00Z","timestamp":1669907940000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41398-021-01727-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,10]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["1727"],"URL":"https:\/\/doi.org\/10.1038\/s41398-021-01727-7","relation":{},"ISSN":["2158-3188"],"issn-type":[{"value":"2158-3188","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,10]]},"assertion":[{"value":"26 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 September 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 October 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 January 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"4"}}